-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FSD Pharma Inc. (NASDAQ:HUGE) Short Interest Up 15.9% in August
FSD Pharma Inc. (NASDAQ:HUGE) Short Interest Up 15.9% in August
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 385,800 shares, a growth of 15.9% from the August 15th total of 332,900 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 60,600 shares, the days-to-cover ratio is currently 6.4 days.
FSD Pharma Stock Up 1.3 %
Shares of HUGE stock traded up $0.01 during trading on Monday, hitting $0.90. 58,545 shares of the stock traded hands, compared to its average volume of 108,672. The firm's fifty day moving average price is $0.93 and its 200-day moving average price is $0.90. FSD Pharma has a 52-week low of $0.69 and a 52-week high of $1.70.
Get FSD Pharma alerts:FSD Pharma (NASDAQ:HUGE – Get Rating) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.21) EPS for the quarter.
Institutional Trading of FSD Pharma
A hedge fund recently bought a new stake in FSD Pharma stock. AdvisorShares Investments LLC bought a new stake in FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 170,431 shares of the company's stock, valued at approximately $148,000. AdvisorShares Investments LLC owned about 0.42% of FSD Pharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.26% of the company's stock.About FSD Pharma
(Get Rating)
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Further Reading
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 385,800 shares, a growth of 15.9% from the August 15th total of 332,900 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 60,600 shares, the days-to-cover ratio is currently 6.4 days.
纳斯达克(FSD Pharma Inc.)是空头股数8月份大幅增长的目标。截至8月31日,空头股数共有38.58万股,较8月15日的33.29万股增长15.9%。大约2.2%的股票被卖空。以日均成交量60,600股计算,目前天数与回补比率为6.4天。
FSD Pharma Stock Up 1.3 %
消防处医药股上升1.3%
Shares of HUGE stock traded up $0.01 during trading on Monday, hitting $0.90. 58,545 shares of the stock traded hands, compared to its average volume of 108,672. The firm's fifty day moving average price is $0.93 and its 200-day moving average price is $0.90. FSD Pharma has a 52-week low of $0.69 and a 52-week high of $1.70.
在周一的交易中,巨型股票的股价上涨了0.01美元,达到0.90美元。该股有58,545股易手,而其平均成交量为108,672股。该公司的50日移动均线价格为0.93美元,200日移动均线价格为0.90美元。FSD Pharma的52周低点为0.69美元,52周高点为1.70美元。
FSD Pharma (NASDAQ:HUGE – Get Rating) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.21) EPS for the quarter.
FSD Pharma(纳斯达克:巨无霸评级)最近一次发布季度收益报告是在8月12日(星期五)。该公司公布了该季度每股收益(0.21美元)。
Institutional Trading of FSD Pharma
FSD Pharma的机构交易
About FSD Pharma
关于消防处药业
(Get Rating)
(获取评级)
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
FSD Pharma Inc.通过其子公司作为一家制药研发公司运营。它的主要候选药物包括正在进行治疗新冠肺炎疾病的第二阶段临床试验的FSD-201。该公司还专注于Lucid-Topch,一种被发现用于潜在治疗抑郁症等神经精神疾病的精神活性分子;以及Lucid-MS,一种获得专利的新化学实体,被证明在临床前模型中可以防止和逆转髓鞘降解,这是多发性硬化症的潜在机制。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免费获取StockNews.com关于FSD Pharma的研究报告(Heavy)
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
- Upwork股价跌入便宜货领域
- 克罗格百货是你的一站式消费者史泰博股票
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《消防局医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FSD Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧